Drug intelligence / Profile preview

CNQ nanoparticles

Development stage: Preclinical
Lead developer: Zhejiang Provincial People's Hospital
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules

Overview

**CNQ nanoparticles** are a preclinical multifunctional nanomedicine developed for hepatocellular carcinoma. The formulation incorporates calcium carbonate, the polycyclic conjugated photothermal small molecule 2Br-NDIA, and quercetin. Under mild photothermal treatment, CNQ activates transient receptor potential vanilloid 1, causing mitochondrial calcium overload, disruption of intracellular calcium homeostasis, and antitumor effects. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39489262/))

Other names: CNQ

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on CNQ nanoparticles.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CNQ nanoparticles.

Explore the full profile